文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

清醒俯卧位在COVID-19成人患者中的应用:个体参与者数据荟萃分析

Awake Prone Positioning in Adults With COVID-19: An Individual Participant Data Meta-Analysis.
PubMed 文献 · JAMA Intern Med · 2025-01-01
一句话结论在COVID-19合并急性低氧性呼吸衰竭成人中,清醒俯卧位与无插管生存增加、插管和住院死亡风险降低相关,每日≥10小时与更好结局相关。

该个体参与者数据荟萃分析纳入14项随机临床试验、共3019例COVID-19合并急性低氧性呼吸衰竭成人患者,评估清醒俯卧位与临床结局的关联。结果显示,清醒俯卧位改善无插管生存(OR 1.42,95%CI 1.20-1.68),降低插管风险(OR 0.70,95%CI 0.59-0.84)和住院死亡风险(OR 0.77,95%CI 0.63-0.95),并延长从入组到插管的时间(MD 0.93天,95%CI 0.43-1.42天)。探索性亚组分析中,各亚组与清醒俯卧位治疗均无显著交互作用;前3天内每日俯卧位时长≥10小时与无插管生存增加相关(OR 1.85,95%CI 1.37-2.49)。

要点

  • 在COVID-19合并急性低氧性呼吸衰竭成人中,清醒俯卧位改善无插管生存(OR 1.42,95%CI 1.20-1.68)。
  • 清醒俯卧位降低插管风险(OR 0.70,95%CI 0.59-0.84)和住院死亡风险(OR 0.77,95%CI 0.63-0.95)。
  • 清醒俯卧位延长从入组到插管的时间(MD 0.93天,95%CI 0.43-1.42天)。
  • 前3天内每日俯卧位时长≥10小时与无插管生存增加相关(OR 1.85,95%CI 1.37-2.49)。
  • 探索性亚组分析中,各亚组与清醒俯卧位治疗均无显著交互作用。

适用人群与场景

  • 纳入标准:成人COVID-19合并急性低氧性呼吸衰竭,随机临床试验报告插管率或死亡率。
  • 共纳入14项随机临床试验、3019例患者;清醒俯卧位组1542例(平均[SD]年龄59.3[14.1]岁;男性1048例[68.0%]),对照组1477例(平均[SD]年龄59.9[14.1]岁;男性979例[66.3%])。

研究设计与关键结果

  • 研究类型:个体参与者数据荟萃分析,纳入14项随机临床试验,共3019例COVID-19合并急性低氧性呼吸衰竭成人患者。
  • 主要终点:清醒俯卧位组无插管生存优于对照组(OR 1.42,95%CI 1.20-1.68)。
  • 次要终点:清醒俯卧位降低插管风险(OR 0.70,95%CI 0.59-0.84)和住院死亡风险(OR 0.77,95%CI 0.63-0.95)。
  • 次要终点:清醒俯卧位延长从入组到插管的时间(MD 0.93天,95%CI 0.43-1.42天)。
  • 探索性亚组分析:年龄小于68岁、体重指数26至30、早期实施清醒俯卧位(即住院至实施不足1天)、脉搏血氧饱和度与吸入氧分数比值155至232、呼吸频率20至26次/分、入组时接受高级呼吸支持的患者中观察到无插管生存改善;但各亚组与清醒俯卧位治疗均无显著交互作用。
  • 前3天内每日清醒俯卧位时长≥10小时与无插管生存增加相关(OR 1.85,95%CI 1.37-2.49)。

证据类型、等级与局限

  • 证据类型:个体参与者数据荟萃分析,纳入14项随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在COVID-19合并急性低氧性呼吸衰竭成人中,清醒俯卧位与无插管生存增加、插管和死亡风险降低相关,包括插管后死亡。
  • 作者认为,延长清醒俯卧位时长(每日≥10小时)与更好结局相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The impact of awake prone positioning (APP) on clinical outcomes in patients with COVID-19 and acute hypoxemic respiratory failure (AHRF) remains uncertain.

OBJECTIVE: To assess the association of APP with improved clinical outcomes among patients with COVID-19 and AHRF, and to identify potential effect modifiers.

DATA SOURCES: PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov were searched through August 1, 2024.

STUDY SELECTION: Randomized clinical trials (RCTs) examining APP in adults with COVID-19 and AHRF that reported intubation rate or mortality were included.

DATA EXTRACTION AND SYNTHESIS: Individual participant data (IPD) were extracted according to PRISMA-IPD guidelines. For binary outcomes, logistic regression was used and odds ratio (OR) and 95% CIs were reported, while for continuous outcomes, linear regression was used and mean difference (MD) and 95% CIs were reported.

MAIN OUTCOMES AND MEASURES: The primary outcome was survival without intubation. Secondary outcomes included intubation, mortality, death without intubation, death after intubation, escalation of respiratory support, intensive care unit (ICU) admission, time from enrollment to intubation and death, duration of invasive mechanical ventilation, and hospital and ICU lengths of stay.

RESULTS: A total of 14 RCTs involving 3019 patients were included; 1542 patients in the APP group (mean [SD] age, 59.3 [14.1] years; 1048 male [68.0%]) and 1477 in the control group (mean [SD] age, 59.9 [14.1] years; 979 male [66.3%]). APP improved survival without intubation (OR, 1.42; 95% CI, 1.20-1.68), and it reduced the risk of intubation (OR, 0.70; 95% CI, 0.59-0.84) and hospital mortality (OR, 0.77; 95% CI, 0.63-0.95). APP also extended the time from enrollment to intubation (MD, 0.93 days; 95% CI, 0.43 to 1.42 days). In exploratory subgroup analyses, improved survival without intubation was observed in patients younger than age 68 years, as well as in patients with a body mass index of 26 to 30, early implementation of APP (ie, less than 1 day from hospitalization), a pulse saturation to inhaled oxygen fraction ratio of 155 to 232, respiratory rate of 20 to 26 breaths per minute (bpm), and those receiving advanced respiratory support at enrollment. However, none of the subgroups had significant interaction with APP treatment. APP duration 10 or more hours/d within the first 3 days was associated with increased survival without intubation (OR, 1.85; 95% CI, 1.37-2.49).

CONCLUSIONS AND RELEVANCE: This IPD meta-analysis found that in adults with COVID-19 and AHRF, APP was associated with increased survival without intubation and with reduced risks of intubation and mortality, including death after intubation. Prolonged APP duration (10 or more hours/d) was associated with better outcomes.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Luo J, Pavlov I, Tavernier E, et al. Awake Prone Positioning in Adults With COVID-19: An Individual Participant Data Meta-Analysis. JAMA Intern Med. 2025. PMID: 40063016. doi:10.1001/jamainternmed.2025.0011

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。